test

Clinical Trials

Breast Cancer

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Disease/Condition: Breast - Female
Principal Investigator: Lajos Pusztai
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Disease/Condition: Breast - Female | Breast - Male | Cancer
Principal Investigator: Maysa Abu-Khalaf
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Disease/Condition: Breast - Female
Principal Investigator: Erin Hofstatter
A Pilot Pre-operative Window Trial of Black Cohosh in Women with Ductal Carcinoma in situ
Disease/Condition: Breast - Female
Principal Investigator: Erin Hofstatter
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
A Randomized Phase II trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Erin Hofstatter
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Disease/Condition: Breast - Female | Breast Cancer
Principal Investigator: Erin Hofstatter
A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Michael DiGiovanna
A Single Arm, Neoadjuvant, Phae II Trial of Pertuzumab and Trastuzumab Administered Concomitantly with Weekly Paclitaxel and FEC for Clinical Stage I-III HER2-Positive Breast Cancer
Disease/Condition: Breast - Female
Principal Investigator: Lajos Pusztai
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Principal Investigator: Sarah Mougalian
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients with Early Stage ER-positive Breast Cancer
Principal Investigator: Tara Sanft
Examination of Epigenetic Changes in Breast Tissue and Peripheral Blood of Women at Average versus Increased Risk of Breast Cancer
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Erin Hofstatter
Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients
Disease/Condition: Breast - Female
Principal Investigator: Debra Brandt
Intra-Operative Specimen Imaging in Breast Cancer Patients Undergoing Standard Partial Mastectomy: A Pilot of the Faxitron BioVision Wedge 3D versus BioVision 2D Imaging
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Anees Chagpar